Yahoo
NasdaqCM - Delayed Quote USD

InspireMD, Inc. (NSPR)

0.6960 +0.0570 (+8.92%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for NSPR
  • Previous Close 0.6390
  • Open 0.6210
  • Bid 0.4445 x 100
  • Ask 0.4610 x 400
  • Day's Range 0.6099 - 0.7124
  • 52 Week Range 0.4300 - 2.2200
  • Volume 342,670
  • Avg. Volume 169,549
  • Market Cap (intraday) 32.356M
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6200
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 3.33
  • Moby Rating Neutral

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.

www.inspiremd.com

127

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NSPR
60.90%
S&P 500 (^GSPC)
7.76%

1-Year Return

NSPR
64.49%
S&P 500 (^GSPC)
9.77%

3-Year Return

NSPR
79.16%
S&P 500 (^GSPC)
68.96%

5-Year Return

NSPR
83.35%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 3.4M
Earnings --
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
1M
2M
3M
0.0%

Analyst Insights

View More

Analyst Price Targets

3.00
3.33 Average
0.6960 Current
4.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/5/2026
Analyst Piper Sandler
Rating Action Reiterates
Rating Overweight
Price Action Lowers
Price Target 4 -> 3

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -85.85%

  • Return on Equity (ttm)

    -202.81%

  • Revenue (ttm)

    10.84M

  • Net Income Avi to Common (ttm)

    -52.48M

  • Diluted EPS (ttm)

    -0.6200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.42M

  • Total Debt/Equity (mrq)

    9.60%

  • Levered Free Cash Flow (ttm)

    -23.11M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: